




The relative strengths and weaknesses of Cytomx Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cytomx Therapeutics Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 9.5% points. The greatest weakness of Cytomx Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 125% points below the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	310,301	Assets	339,411
Cost of Goods Sold	0	Liabilities	250,032
Intangible Assets	949	Expenses	153,354
Liabilities, Current	106,316	Revenues	69,573
Liabilities, Non-Current	143,716	Stockholders Equity	89,379
Other Assets	22,201	Net Income	-167,413
Other Compr. Net Income	-195	Comprehensive Net Income	-167,510
Other Expenses	0	BaseVar	448,098
Other Liabilities	0	ECR before LimitedLiability	9.3%
Other Net Income	-83,632	Economic Capital Ratio	150%
Other Revenues	69,573		
Property and Equipment	5,960		
Research and Development	114,194		
Selling, General and Administrative Expense	39,160		